AnaptysBio (NASDAQ:ANAB) Sees Strong Trading Volume

AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) saw an uptick in trading volume on Tuesday . 435,513 shares changed hands during trading, an increase of 35% from the previous session's volume of 323,309 shares.The stock last traded at $23.39 and had previously closed at $21.30.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Wedbush upgraded shares of AnaptysBio from a "neutral" rating to an "outperform" rating and boosted their price target for the stock from $20.00 to $34.00 in a research note on Tuesday, March 12th. Piper Sandler started coverage on AnaptysBio in a report on Friday, February 16th. They set an "overweight" rating and a $80.00 price target for the company. Wells Fargo & Company assumed coverage on AnaptysBio in a report on Thursday, April 11th. They set an "overweight" rating and a $56.00 price objective on the stock. Leerink Partnrs reiterated an "outperform" rating on shares of AnaptysBio in a research report on Tuesday, April 16th. Finally, Stifel Nicolaus assumed coverage on shares of AnaptysBio in a report on Wednesday, February 21st. They issued a "buy" rating and a $50.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, AnaptysBio presently has a consensus rating of "Moderate Buy" and an average price target of $46.22.

AnaptysBio Stock Performance

The company has a market capitalization of $664.97 million, a P/E ratio of -4.00 and a beta of -0.30. The firm's fifty day moving average is $22.88 and its 200 day moving average is $20.65.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.74) by $0.15. The firm had revenue of $9.01 million during the quarter, compared to analyst estimates of $3.28 million. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. On average, analysts forecast that AnaptysBio, Inc. will post -6.17 EPS for the current year.

Insider Transactions at AnaptysBio

In other AnaptysBio news, CEO Daniel Faga sold 3,000 shares of the company's stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $21.42, for a total value of $64,260.00. Following the transaction, the chief executive officer now directly owns 749,087 shares in the company, valued at approximately $16,045,443.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Daniel Faga sold 3,000 shares of AnaptysBio stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $21.42, for a total value of $64,260.00. Following the completion of the sale, the chief executive officer now directly owns 749,087 shares in the company, valued at $16,045,443.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric J. Loumeau sold 5,000 shares of the company's stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the completion of the sale, the insider now directly owns 3,240 shares of the company's stock, valued at $81,000. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 153,940 shares of company stock worth $3,513,773. 35.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On AnaptysBio

A number of large investors have recently bought and sold shares of ANAB. Allspring Global Investments Holdings LLC purchased a new position in shares of AnaptysBio in the 1st quarter valued at $38,000. China Universal Asset Management Co. Ltd. boosted its position in AnaptysBio by 350.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company's stock valued at $66,000 after purchasing an additional 2,390 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in AnaptysBio by 134.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company's stock valued at $106,000 after purchasing an additional 3,381 shares during the last quarter. Quest Partners LLC bought a new position in AnaptysBio in the fourth quarter worth about $119,000. Finally, SG Americas Securities LLC bought a new position in AnaptysBio in the fourth quarter worth about $126,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.